The FLT3 inhibitors midostaurin and gilteritinib have received EMA and Food and Drug Administration (FDA) approval for treatment‐naive FLT3‐mutated AML and relapsed/refractory (R/R) FLT3‐mutated AML, respectively. The gene discussed is FLT3; the disease is acute myeloid leukemia.